1Urban ML, Palmisano A, Nicastro M, Corradi D, Buzia C, Vaglio A. İdiopathic and secondary forms of retroperitoneal fibrosis: A diagnostic approach. Le Revue de medecine interne 2015;36:15-21.
2Van Bommel EF, Jansen I, Hendriksz TR, Aarnoudse AL. Idıopathic retroperitoneal fibrosis:prospective evaluation of incidence and clinicoradiologic presentation. Medicine 2009;88:193-201.
3Adnan S, Bouraoui A, Mehta S, Banerjee S, Jain S, Dasgupta B. Retroperitoneal fibrosis; a single-centre case experience with literature review. Rheumatology Advnaces in Practice 2018;0:1-8.
4Fernando A, Pattison J, Horsfield C, et al. A lot of questions (and a few answers) in retroperitoneal fibrosis. BJU Int 2016;117:16-9.
5Kermani T, Crownson C, Achenbcah S, Luthra H. Idiopathic retroperitoneal fibrosis: a retrospective review of clinical presentation, treatment and outcomes. Mayo Clin roc 2011;86:297-303.
6Scheel PJ, Feeley N. Retroperitoneal fibrosis The clinical, laboratory and radiographic presentation. Medicine 2009;88:202-7.
7Vaglio A, Maritati F. Idiopathic retroperitoneal fibrosis. J Am Soc Nephrol 2016;27:1880-9.
8Vaglio A, Palmisano A,Corradi D, Salvarani C, Buzio C. Retroperitoneal fibrosis:evolving concepts. Rheum Dis Clin North Am 2007;33:803-17.
9van Bommel EF, Hendriksz TR, Huiskes AW, Zeegers AG. Brief communication: tamoxifen therapy for nonmalignant retroperitoneal fibrosis. Ann Intern Med 2006;144:101-6.
10Binder M, Uhl M, Wiech T, Kollert F, Thiel J, Sass JO, et al. Cyclophosphamide is a highly effective and safe induction therapy in chronic periaortitis: a long-term follow-up of 35 patients with chronic periaortitis. Ann Rheum Dis 2012;71:311-2.
11Marcolongo R, Tavolini IM, Laveder F, Busa M, Noventa F, Bassi P, et al. Immunosuppressive therapy for idiopathic retroperitoneal fibrosis: a retrospective analysis of 26 cases. Am J Med 2004;116:194-7.
12Vaglio A, Catanoso MG, Spaggiari L, Magnani L, Pipitone N, Macchioni P, et al. Interleukin-6 as an inflammatory mediator and target of therapy in chronic periaortitis. Arthritis Rheum 2013;65:2469-75.
13Maritati F, Corradi D, Versari A, Casali M, Urban ML, Buzio C, et al. Rituximab therapy for chronic periaortitis. Ann Rheum Dis 2012;71:1262-4.
14Wallace ZS, Naden RP, Chari S, Chai HK, DellaTorre E, Dicaire JF, et al. The 2019 American College of Rheumatology/European League against Rheumatism Classification Criteria for IgG4 related disease. Ann Rheum Dis 2020;7-19.
15Koo Bs, Koh YW, Kim YJ, Kim YG, Lee CK. Clinicopathologic characteristics of IgG4-related retroperitoneal fibrosis among patients initially diagnosed as having idiopathic retroperitoneal fibrosis. Modern Rheumatology 2015;25:194-8.
16Zen Y, Onodera M, Inoue D, Kitao A, Matsui O, Nohara T, et al. Retroperitoneal fibrosis: a clinicopathologic study with respect to immunoglobulin G4. Am J Surg Pathol. 2009;33:1833-9.